Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

Sonja Zweegman, Claudia A M Stege, Einar Haukas, Fredrik H Schjesvold, Mark-David Levin, Anders Waage, Rineke B L Leys, Saskia K Klein, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Dorota Knut-Bojanowska, Ellen van der Spek, Asta Svirskaite, Anja Klostergaard, Morten Salomo, Celine Blimark, Paula F Ypma, Ulf-Henrik Mellqvist, Pino J PoddigheMarian Stevens-Kroef, Niels W C J van de Donk, Pieter Sonneveld, Markus Hansson, Bronno van der Holt, Niels Abildgaard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OriginalsprogEngelsk
TidsskriftHaematologica
ISSN0390-6078
DOI
StatusE-pub ahead of print - 13. feb. 2020

Citationsformater

Zweegman, S., Stege, C. A. M., Haukas, E., Schjesvold, F. H., Levin, M-D., Waage, A., Leys, R. B. L., Klein, S. K., Szatkowski, D., Axelsson, P., Hieu Do, T., Knut-Bojanowska, D., van der Spek, E., Svirskaite, A., Klostergaard, A., Salomo, M., Blimark, C., Ypma, P. F., Mellqvist, U-H., ... Abildgaard, N. (2020). Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. https://doi.org/10.3324/haematol.2019.240374